Clinical Trial Update: Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating whether maraviroc improves immunological recovery (CD4 counts) in HIV-1–infected patients with discordant CD4 counts below 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: Hospital Clinic of Barcelona | Conditions: HIV-1 Infection | Phase 4 | Status: UNKNOWN